Zobrazeno 1 - 10
of 80
pro vyhledávání: '"Federica Cuppone"'
Autor:
Luisa Carbognin, Sara Pilotto, Michele Milella, Vanja Vaccaro, Matteo Brunelli, Anna Caliò, Federica Cuppone, Isabella Sperduti, Diana Giannarelli, Marco Chilosi, Vincenzo Bronte, Aldo Scarpa, Emilio Bria, Giampaolo Tortora
Publikováno v:
PLoS ONE, Vol 10, Iss 6, p e0130142 (2015)
The potential predictive role of programmed death-ligand-1 (PD-L1) expression on tumor cells in the context of solid tumor treated with checkpoint inhibitors targeting the PD-1 pathway represents an issue for clinical research.Overall response rate (
Externí odkaz:
https://doaj.org/article/ee78a6d6da5f4636b0914b280cfd4efd
Autor:
Luisa Carbognin, Francesca Pellini, Emilio Bria, Elena Fiorio, Veronica Parolin, Rolando Nortilli, Davide Lombardi, Giampaolo Tortora, Alessandro De Toma, Sara Pilotto, Valentina Zambonin, Federica Cuppone, Giovanni Paolo Pollini
Publikováno v:
Expert opinion on biological therapy. 17(4)
Angiogenesis plays a fundamental role in breast cancer (BC) growth, progression and metastatic spread. After the promising introduction of bevacizumab for the treatment of advanced BC, the initial enthusiasm decreased when the FDA withdrew its approv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9af393ee342bf7b611db9cb08e1c67a
https://pubmed.ncbi.nlm.nih.gov/28133971
https://pubmed.ncbi.nlm.nih.gov/28133971
Autor:
Emilio Bria, Giulia Grizzi, Mario Caccese, Anna Caliò, S. Petraglia, Matteo Brunelli, Luisa Carbognin, Giampaolo Tortora, Aldo Scarpa, Roberto Ferrara, Federica Cuppone, Sara Pilotto
The treatment of patients with ALK-rearranged non-small-cell lung cancer was completely revolutionized by the introduction of Crizotinib, a small molecule inhibiting ALK, MET and ROS1. Given that resistance occurs within approximately 12 months, in o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62c131387eb0c8998d5a9bdc6a49d024
http://hdl.handle.net/11562/949847
http://hdl.handle.net/11562/949847
Adjuvant therapy for resected early-stage small-cell lung cancer: is now time to rethink about that?
Autor:
Giampaolo Tortora, Roberto Ferrara, Emilio Bria, Federica Cuppone, Mario Caccese, Sara Pilotto
Small-cell lung cancer (SCLC) has historically been considered a highly chemo-radiosensitive malignancy, rarely susceptible of surgical resection due to advanced stage presentation with bulky nodal disease and frequent systemic involvement. Actually,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::676c3cdac72c392ecc21680f158b0987
http://hdl.handle.net/11562/974619
http://hdl.handle.net/11562/974619
Autor:
Alain Gelibter, Davide Melisi, Federica Cuppone, Emilio Bria, Vanja Vaccaro, Giampaolo Tortora, Francesco Cognetti, Michele Milella, Ludovica Ciuffreda, Maria Simona Pino
Publikováno v:
Expert Opinion on Therapeutic Targets. 15:1183-1196
Pancreatic cancer treatment remains a challenge for clinicians and researchers. Despite undisputable advances in the comprehension of the molecular mechanisms underlying cancer development and progression, early disease detection and clinical managem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d54cb0943b6966431e7f8a4f7cac8bb
https://doi.org/10.1517/14728222.2011.607438
https://doi.org/10.1517/14728222.2011.607438
Autor:
Michele Milella, Emilio Bria, Paolo Carlini, Francesco Cognetti, Federica Cuppone, Vanja Vaccaro
Publikováno v:
Expert Review of Anticancer Therapy. 10:1239-1253
Aromatase inhibitors (AIs) are becoming the hormonal treatment of choice for postmenopausal women with early breast cancer. Large, well-controlled clinical studies have established the efficacy and safety of initial adjuvant therapy with letrozole or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a15793282d52ca645b208c77d706554
https://doi.org/10.1586/era.10.54
https://doi.org/10.1586/era.10.54
Autor:
Isabella Sperduti, Emilio Bria, Fiorentino Izzo, Francesco Tropea, Cecilia Nisticò, Armando Carpino, Francesco Cognetti, Monica Fornier, Edmondo Terzoli, Vanja Vaccaro, Federica Cuppone
Publikováno v:
Anti-Cancer Drugs. 20:109-114
A feasibility-phase II study was conducted to assess the cardiotoxicity of weekly trastuzumab, epirubicin, and paclitaxel in patients with human epidermal growth factor receptor-2-positive metastatic breast cancer. Untreated patients with human epide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e15a7e9598239499d5e4b357ba5b1f65
https://doi.org/10.1097/cad.0b013e32831bc09b
https://doi.org/10.1097/cad.0b013e32831bc09b
Autor:
Michele Milella, Federica Cuppone, Emilio Bria, Isabella Sperduti, Harry Raftopoulos, Diana Giannarelli, Richard J. Gralla, Francesco Cognetti, Edmondo Terzoli, Paolo Carlini
Publikováno v:
Lung Cancer. 63:50-57
Several randomized trials investigating the benefit of adjuvant chemotherapy after surgery in non-small cell lung cancer (NSCLC) have provided conflicting results. With over 7000 patients included, we analyzed results of 13 reports over the past 10 y
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d09b14cbd6f3afde4fb118c8461b4f9
https://doi.org/10.1016/j.lungcan.2008.05.002
https://doi.org/10.1016/j.lungcan.2008.05.002
Autor:
Kathleen I. Pritchard, Sonal Gandhi, Sunil Verma, Francesco Cognetti, Paolo Carlini, Diana Giannarelli, Emilio Bria, Michelle Milella, Cecilia Nisticò, Edmondo Terzoli, Federica Cuppone
Publikováno v:
Cancer. 112:260-267
BACKGROUND. Despite the advantages from using aromatase inhibitors (AIs) compared with tamoxifen for early breast cancer, an unexpectedly greater number of grade 3 and 4 cardiovascular events (CVAE) (as defined by National Cancer Institute of Canada-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b67139e147acd00e64d74d9000edd0b6
https://doi.org/10.1002/cncr.23171
https://doi.org/10.1002/cncr.23171
Autor:
Edmondo Terzoli, Alain Gelibter, Cecilia Nisticò, Michele Milella, Federica Cuppone, Paolo Carlini, Emilio Bria, Francesco Cognetti, Enzo Maria Ruggeri, Diana Giannarelli, Maria Simona Pino
Publikováno v:
Cancer. 110:525-533
BACKGROUND. Several attempts have been made at improving the efficacy of gemcitabine in advanced pancreatic cancer by combining it with other chemotherapeutic or molecularly targeted agents. However, randomized trials have produced conflicting result
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f82d9def13182e34585b51f79808f25
https://doi.org/10.1002/cncr.22809
https://doi.org/10.1002/cncr.22809